Clinical trials: Neoplasm, Ovarian
Carcinoma, Ovarian Neoplasm
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Our hypothesis is: the nutritional supplement Ocoxin-viusid improves the quality of life of patients, including a better tolerance to neoadjuvant chemotherapy.
- Conditions
- Carcinoma, Ovarian Neoplasm, Endocrine Gland Neoplasm, Urogenital Neoplasms
- Trial name
- NCT03562897
- Testing
- Ocoxin-Viusid
- Where
- Cuba
- Volunteers
- 40 people
- Sponsor
- Catalysis SL
Polycystic Ovary Syndrome
GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)
Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often…
- Trial name
- NCT04876027
- Testing
- GLP-1 RAs, calorie restricted diet
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shanghai 10th People's Hospital
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase II trial is studying how well giving bevacizumab together with erlotinib works in treating patients with recurrent or metastatic ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00126542
- Testing
- bevacizumab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor Positive, HER2/Neu Negative
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
This clinical trial studies fluorine F 18 fluorothymidine (FLT) positron emission tomography (PET) in measuring treatment response in patients with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- NCT01928186
- Testing
- Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Washington
Ovarian Cancer, Peritoneal Cancer
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III suboptimally cytoreduced or…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Stage 3 Cancer
- Trial name
- NCT00408070
- Testing
- Bevacizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UConn Health
Ovarian Cancer, Peritoneal Metastases
Diffusion-weighted Imaging Study in Cancer of the Ovary
This project seeks to develop a quantitative imaging biomarker for evaluating and monitoring treatment response in ovarian cancer metastases and assess its potential in monitoring treatment response.
- Trial name
- DISCOVAR (NCT01505829)
- Where
- 6 sites in United Kingdom
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Recurrent Ovarian Cancer, Fallopian Tube Cancer
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
The primary objective of this study is to investigate the feasibility, tolerability and safety of surgical debulking and resection with heated intraoperative chemotherapy (HIPEC) followed by repeated intraperitoneal chemotherapy…
- Trial name
- HIPEC (NCT01659554)
- Testing
- Cisplatin, Doxorubicin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Platinum-resistant Ovarian Cancer (PROC), Immunotherapy
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib…
- Trial name
- NCT06600841
- Testing
- Immunotherapy（Adebrelimab）
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fujian Cancer Hospital
Advanced Solid Tumors, Merkel Cell Carcinoma
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including…
- Trial name
- NCT04047251
- Testing
- FF-10850 Topotecan Liposome Injection
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Ovarian Cancer
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
The purpose of this study is to compare the effectiveness (progression free survival) of the experimental combination of carboplatin + liposomal doxorubicin with the standard combination of carboplatin + paclitaxel in first line…
- Trial name
- NCT00326456
- Testing
- liposomal doxorubicin, carboplatin, paclitaxel
- Where
- 38 sites in Italy, Portugal and 1 more
- Volunteers
- 820 people
- Sponsor
- National Cancer Institute, Naples
Polycystic Ovary Syndrome
Metformin Treatment in Adolescent Patients With PCOS: A Long-term, Winning Metabolic Choice.
This study aimed to understand whether metformin therapy can improve insulin resistance in adolescent PCOS patients, both during treatment and after discontinuation, and to evaluate its action on the hormonal and metabolic…
- Trial name
- NCT06015594
- Testing
- Metformin
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Cagliari
Ovarian Cancer
A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer
This study was designed to explore the safety and efficacy of Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy or Fluzoparib monotherapy in patients with platinum-resistant recurrent ovarian cancer.
- Trial name
- NCT05170594
- Testing
- Bevacizumab, chemotherapy, Fluzoparib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Colon Cancer, Gastric Cancer
Integrated Care Pathway in Oncology (PASSION)
A centralized unit for integrated management of care pathway in Oncology has been created. This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy, imaging, oncologist...).
- Conditions
- Colon Cancer, Gastric Cancer, Pancreatic Cancer, Thoracic Neoplasms
- Trial name
- PASSION (NCT04235556)
- Testing
- Care pathway unit
- Where
- France
- Volunteers
- 1,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ovarian Cancer, Fallopian Tube Cancer
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
This research study is testing the use of a smartphone app to identify clinically meaningful changes in the behaviors of patients' with gynecological cancers by using passively collected smartphone data.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer
- Trial name
- SIGNAL (NCT04368130)
- Testing
- SIGNAL
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Primary Peritoneal Carcinoma
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of…
- Trial name
- NCT00083928
- Testing
- Å6 subcutaneous injection
- Where
- 24 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ångstrom Pharmaceuticals
Ovarian Cancer, Chemotherapeutic Toxicity
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer
- Trial name
- NCT03393507
- Testing
- Apatinib, Taxus + platinum
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The People's Hospital of Leshan
Polycystic Ovary Syndrome, Diet Habit
Advanced Glycation End Products and Dietary Intervention in Polycystic Ovary Patients
Recently, the negative effects of advanced glycation end products on the pathophysiology of some diseases have attracted attention.
- Trial name
- NCT05830487
- Testing
- Low AGE diet with reduced energy and fat, Energy and fat-reduced normal diet
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people
- Sponsor
- Hacettepe University
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Polycystic Ovary Syndrome
A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation
This is a Phase IV, prospective, observational, single arm, multicenter trial to identify the population at high risk of overstimulation associated with signs and symptoms of PCOS and examines the utility of 12.5 international…
- Trial name
- ARTIST (NCT02607293)
- Testing
- Gonal-f®, Long GnRH agonist, GnRH antagonist
- Where
- Germany
- Volunteers
- 1,064 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumors, Ovarian Cancer
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
This study consists of two parts. Part 1 is a dose-escalation/safety evaluation to provisionally identify a dose and regimen of SY-1365 for further evaluation in Part 2.
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03134638
- Testing
- SY-1365 (Part 1), Carboplatin, Fulvestrant
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 107 people
- Sponsor
- Syros Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.